Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"
05-13 Elpida Therapeutics and Catalent Enter Strategic Partnership for Late-Phase Aav Manufacturing CI
04-09 Cartherics Pty Ltd and Catalent Inc Expand Commercial License Agreement CI
03-11 Gelmedix and Catalent Enter Global Partnership for Development and Clinical Manufacturing of Ipsc-Derived Cell Therapies in Ocular and Retinal Diseases CI
02-18 Catalent and S.Biomedics Announces Partnership to Develop and Manufacture Ted-A9 CI
01-12 Smartcella Holding AB and Catalent, Inc. Sign Nonexclusive License Agreement for Gmp Ipscs CI
11-04 Catalent, Inc.'s SMARTag ADC Pipeline and New Enhanced Conjugates Offering Featured at 16th World ADC San Diego CI
25-09-04 Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research CI
25-06-26 GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent CI
25-04-23 Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities CI
25-04-15 Lisata Therapeutics, Inc. Announces Research License with Catalent, Inc CI
25-02-20 Catalent, Inc. Appoints Susan Mahony, Marie-France Tschudin and Tim Walbert to Its Board of Directors CI
25-02-03 Ardena Holding NV completed the acquisition of Oral Solids Development and Small-Scale Manufacturing Facility in Somerset, NJ from Catalent, Inc.. CI
25-02-03 Ardena Holding NV acquired Drug product manufacturing facility in Somerset, New Jersey of Catalent, Inc. CI
Manager TitleAgeSince
Chief Executive Officer 54 2022-06-30
Director of Finance/CFO 54 2023-07-04
Chief Operating Officer - 2025-08-31
Director TitleAgeSince
Director/Board Member 54 2022-06-30
Director/Board Member 59 -
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap.
24-12-17Issuer sale

Director

47,984 0.0264%
24-12-17Issuer sale

Director

70,118 0.0386%
24-12-17Issuer sale

Controller/Auditor

19,820 0.0109%
Logo Catalent, Inc.
Catalent, Inc. is specialized in pharmaceutical outsourcing services. The group offers solutions for the development and formulation of drugs, biological products and animal health products. Net sales break down by activity as follows: - provision of development services and clinical supply services (62.2%); - subcontracted manufacturing services (37.8%). Net sales are distributed geographically as follows: the United States (62.7%), Europe (30.6%) and other (6.7%).
Employees
16,900
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. CTLT Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!